Abstract
The 90 kDa heat shock proteins (Hsp90) represent a class of molecular chaperones responsible for the maturation and stabilization of many oncogenic proteins. Disrupting the ability of ATP to bind and facilitate the operation of Hsp90 has emerged as a promising approach toward cancer chemotherapeutic development. While numerous Hsp90 inhibitory scaffolds have been identified, progress through the clinic has revealed many obstacles that should be addressed in future analogue development. Recent reports of the complications, pitfalls, and downstream effects associated with Hsp90 inhibition are discussed herein, in hopes of providing a reference that can be used to guide the future design of Hsp90 inhibitory scaffolds.
Original language | English (US) |
---|---|
Pages (from-to) | 4983-4987 |
Number of pages | 5 |
Journal | Bioorganic and Medicinal Chemistry Letters |
Volume | 20 |
Issue number | 17 |
DOIs | |
State | Published - Sep 1 2010 |
Externally published | Yes |
Bibliographical note
Funding Information:The authors thank the NIH/NCI CA109265, The Madison and Lila Self Graduate Fellowship (A.S.D.), and The American Foundation for Pharmaceutical Education Pre-doctoral Fellowship (A.S.D.) for financial support.
Keywords
- Anti-cancer
- Hsp90
- Resistance